Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aged interleukin-10tm1Cgn chronically inflamed mice have substantially reduced fat mass, metabolic rate, and adipokines.

PloS one·2017
Same author

Redefining Unexplained Anemia in Elderly-Reply.

JAMA internal medicine·2017
Same author

Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial.

JAMA internal medicine·2017
Same author

Dynamic control of hepatic Plasmodium numbers by hepcidin despite elevated liver iron during iron supplementation.

Microbes and infection·2015
Same author

Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.

Pediatric nephrology (Berlin, Germany)·2014
Same author

RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.

American journal of hematology·2014
Same journal

Cardiovascular Prevention in Older Adults: From Estimation to Treatment.

Clinics in geriatric medicine·2026
Same journal

Preventive Cardiology for the Clinically Complex Older Adult.

Clinics in geriatric medicine·2026
Same journal

A Preventive Neurology Perspective on Promoting Brain Health and Preventing Cardiovascular Disease.

Clinics in geriatric medicine·2026
Same journal

Secondary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Primary Prevention in Older Adults: Putting It All Together.

Clinics in geriatric medicine·2026
Same journal

Managing Bleeding Risk in Older Adults: Antithrombotics and Anticoagulants.

Clinics in geriatric medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Anemia in frailty.

Cindy N Roy1

  • 1Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. Croy6@jhmi.edu

Clinics in Geriatric Medicine
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Anemia is common in older adults and linked to decline and mortality. However, evidence for treatment benefits is lacking, leading to undertreatment in geriatric care.

More Related Videos

Identifying Frailty Using Point-of-Care Ultrasonography: Image Acquisition and Assessment
04:00

Identifying Frailty Using Point-of-Care Ultrasonography: Image Acquisition and Assessment

Published on: July 26, 2024

Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

Related Experiment Videos

Last Updated: Jun 6, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Identifying Frailty Using Point-of-Care Ultrasonography: Image Acquisition and Assessment
04:00

Identifying Frailty Using Point-of-Care Ultrasonography: Image Acquisition and Assessment

Published on: July 26, 2024

Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

Area of Science:

  • Gerontology
  • Hematology
  • Internal Medicine

Background:

  • Anemia is prevalent in older adults, correlating with functional decline, disability, and mortality.
  • Potential mechanisms include reduced oxygen delivery to tissues or shared biologic mediators with age-related deterioration.
  • The medical community disputes the extent of intervention for anemia in this population.

Purpose of the Study:

  • To review the problem of anemia in older adults, focusing on the frail elderly.
  • To assess the evidence base for anemia treatment in this demographic.
  • To identify options for advancing the field of geriatric anemia management.

Main Methods:

  • Literature review focusing on epidemiologic data and clinical trial evidence.
  • Analysis of the risks and benefits of anemia interventions in older adults.
  • Assessment of current guidelines and gaps in geriatric anemia care.

Main Results:

  • Epidemiologic data show a clear link between anemia and adverse outcomes in older adults.
  • Clinical trial evidence for the efficacy of anemia treatment in improving physical performance or reducing mortality is insufficient.
  • Anemia is often untreated in geriatric settings due to lack of guidelines and concerns about adverse events.

Conclusions:

  • Significant gaps exist in the evidence base for treating anemia in older adults.
  • The risks of adverse events with interventions like transfusions and erythroid-stimulating agents must be considered.
  • Further research is needed to establish effective and safe treatment strategies for geriatric anemia.